Business Context and Reporting Period
This Form 8-K was filed by Vickers Vantage Corp. I on October 28, 2022, under Item 8.01, Other Events. Vickers is pursuing a business combination with Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. Under the Merger Agreement, Vantage Merger Sub Inc. would merge with and into Scilex, with Scilex surviving as a wholly owned subsidiary of Vickers.
The SEC declared the related Form S-4 registration statement effective on October 28, 2022. Vickers scheduled an extraordinary general meeting for November 9, 2022, with a record date of October 20, 2022, to vote on the proposed merger and related proposals.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other historical financial metrics.
The filing states that the amount of cash available at closing remains uncertain because it depends partly on the cash remaining in Vickers’ trust account and potential shareholder redemptions. The Merger Agreement does not require a minimum level of trust-account funding for closing.
Material Changes Versus the Prior Comparable Period
No period-over-period financial comparison is presented. The principal disclosed development is procedural: the registration statement became effective, and the shareholder meeting was scheduled.
Guidance, Outlook, Risks, and Unusual Items
- No formal financial guidance is provided.
- Management describes forward-looking expectations concerning completion of the merger, integration, potential synergies, revenue opportunities, future operating performance, and post-closing governance.
- Completion depends on shareholder approvals and satisfaction of other closing conditions, including the net tangible assets condition. The merger agreement could also be amended or terminated.
- Material redemption requests could reduce cash available to Scilex, potentially limiting funding for short-term operations and research and development.
- Other risks include failure to obtain or maintain Nasdaq listing, transaction costs, litigation, regulatory changes, competition, growth and profitability challenges, customer and employee retention, COVID-19 effects, and uncertainty regarding how long Scilex’s available cash will fund operations.
- The filing includes customary forward-looking statement disclaimers and cautions that actual results may differ materially from expectations.
Facts an Investor Should Verify
- Whether Vickers shareholders approved the merger at the November 9, 2022 meeting.
- The final trust-account balance, redemption levels, and cash delivered to Scilex at closing.
- Whether all other closing conditions, including the net tangible assets condition, were satisfied.
- The final ownership, capitalization, ticker symbols, and Nasdaq listing of the combined company.
- Scilex’s financial statements, operating cash needs, research and development funding requirements, and subsequent liquidity position.
- The definitive Proxy Statement/Prospectus and subsequent SEC filings for transaction terms, risk factors, and information concerning participant interests.